2019 Archived Content

PLENARY KEYNOTE PANEL

Wednesday, January 16 | 2:00 - 3:05 pm

PepTalk Perspectives: Point-Counterpoint Discussions

POINT:
“Change is inevitable. Progress is a choice.”
Dean Lindsey

COUNTERPOINT:
“Permanence, perseverance, and persistence in spite of all obstacles, discouragements, and impossibilities: It is this, that in all things distinguishes the strong soul from the weak.”
Thomas Carlyle

IT IS HUMAN NATURE to resist change, especially in the ultraconservative biopharmaceutical industry. Despite this, there is a corresponding desire to make things better whenever possible. However, do advances in technology always result in progress? By design, PepTalk’s eight Pipelines cover a range of topics from R&D discovery to product development where exciting new developments are presented, each with the potential to have significant impact on the discovery and product development lifecycle. Are these changes universally positive? The positive-negative viewpoint may differ depending on a company’s or individual’s perspective.

In thought-provoking point-counterpoint discussions, panelists address the impact and implications of new technology and other advances on accelerating biopharma product development, with topics including:

» Dealing with Regulatory Reform
» Pros and Cons of Accelerating Time to Market
» Impact of Implementing New Technologies
» Impact of Adopting New Therapies and Targets
» What, Where, and When Impact of Big Data

2:00 pm Plenary Keynote Introduction

Norman Packard, PhD, CEO, Daptics

2:10 Plenary Keynote Panel

Moderator:
Howard Levine, PhD, President and CEO, BioProcess Technology Consultants

Panelists:
George Badescu, PhD, Vice President, Scientific Affairs, Heidelberg Pharma AG

Manon Cox, PhD, Co-Founder & CEO, NextWaveBio

Zhimei Du, PhD, Director, Bioprocess & Clinical Manufacturing, Merck

Paul Jorjorian, Vice President, BioProcess Sciences, Thermo Fisher Scientific

Marina Kirkitadze, PhD, Deputy Director, Head of Biophysics and Conformation Unit, Analytical R&D Biochemistry, Sanofi Pasteur, Canada

Stefan R. Schmidt, PhD, MBA, Head, Operations (COO), BioAtrium AG

3:05 Close of Plenary Keynote Panel

Additional Conference Keynote Speakers

Tara Arvedson, PhD, Director, Oncology Research, Amgen, Inc.

Steven Cramer, PhD, William Weightman Walker Professor, Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute

Matthew P. DeLisa, PhD, William L. Lewis Professor, Chemical & Biomolecular Engineering, Cornell University

Rakesh Dixit, PhD, Vice President and Global Head, Translational Sciences-Biologics Safety Assessment, MedImmune, LLC

Jennifer Dumont, PhD, Executive Director, Medical Affairs, Bioverativ, Inc.

Isidro Hotzel, PhD, Senior Scientist, Genentech

Alan K. Hunter, PhD, Director, Purification Process Sciences, MedImmune, LLC

Paul Imbach, MD, Professor, Ped. Oncology/Hematology, University of Basel, Switzerland

Stephen Albert Johnston, PhD, CEO, Calviri, Inc.; Director and Professor, Biodesign Center for Innovations in Medicine, Arizona State University

Alexander (Sasha) Kabanov, PhD, DrSci, Distinguished Professor, Eshelman School of Pharmacy, University of North Carolina and Chapel Hill

Satoshi Ohtake, PhD, Senior Director, Pharmaceutical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer, Inc.

Takeshi Omasa, PhD, Professor, Department of Material and Life Science, Graduate School of Engineering, Osaka University

Palani Palaniappan, PhD, Head, Tech Ops & Andover Site, Sarepta Therapeutics

Bernhard Palsson, PhD, Galletti Professor, Bioengineering; Principal Investigator, Systems Biology Research Group, Bioengineering; Professor, Pediatrics, University of California, San Diego